Trusted Resources: Education
Scientific literature and patient education texts
Combination Therapy With Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
source: Journal of clinical medicine
year: 2021
authors: Mirea A,Shelby ES,Axente M,Badina M,Padure L,Leanca M,Dima V,Sporea C
summary/abstract:Spinal muscular atrophy (SMA) is a neuromuscular progressive disease, characterized by decreased amounts of survival motor neuron (SMN) protein, due to an autosomal recessive genetic defect. Despite recent research, there is still no cure. Nusinersen, an antisense oligonucleotide acting on the gene, is intrathecally administered all life long, while onasemnogene abeparvovec-xioi, a gene therapy, is administered intravenously only once. Both therapies have proven efficacy, with best outcomes obtained when administered presymptomatically. In recent years, disease-modifying therapies such as nusinersen and onasemnogene abeparvovec-xioi have changed the natural history of SMA.
organization: Faculty of Midwifery and Nursing, University of Medicine and Pharmacy "Carol Davila", 37 Dionisie Lupu Street, 020021 Bucharest, Romania.DOI: 10.3390/jcm10235540
read more
Related Content
-
A Caregiver’s Guide to ZolgensmaIndication ZOLGENSMA® (onasemnogene abe...
-
SMA and Nusinersen (Spinraza) the Story so farhttps://slideplayer.com/slide/14664651/...
-
Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database AnalysisSpinal muscular atrophy (SMA) is a rare,...
-
Stanford Healthcare – Spinal Muscular AtrophyStanford Neuromuscular Program has exten...
-
Axonal Excitability Changes in Children With Spinal Muscular Atrophy Treated With NusinersenSpinal muscular atrophy (SMA) is associa...
-
Every Day You Don’t Lose, You Are WinningJennifer Summers, 35, is an optimistic, ...
-
Despite Taking Spinraza, SMA Type 1 Children Show Nonmotor ProblemsDespite its well-reported benefits in mo...